Galera Therapeutics, Inc.
- Jurisdiction
United States - ISIN
US36338D1081 (GRTX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. Read full profile
Stock price
Fundamentals
- Net revenue
€0.00 - Gross margin
0.0% - EBIT
-€12.42M - EBIT margin
0.0% - Net income
-€11.31M - Net margin
0.0%
Statement period: - (published )
Dividends
No dividend payouts